Clements, C., G. Evans, S. Dittman, and A. Reeler. 1999. Vaccine safety concerns everyone. Vaccine October 29(17 Suppl 3):S90-S94.

CMS (Centers for Medicare and Medicaid Services). 2006. Medicaid managed care enrollment report. (accessed April 21, 2008).

Colgrove, J., and R. Bayer. 2005. Could it happen here? Vaccine risk controversies and the specter of derailment. Health Affairs 24(3):729-739.

Cutts, F. T., S. M. A. Zaman, G. Enwere, S. Jaffar, O. S. Levine, J. B. Okoko, C. Oluwalana, A. Vaughan, S. K. Obaro, A. Leach, K. P. McAdam, E. Biney, M. Saaka, U. Onwuchekwa, F. Yallop, N. F. Pierce, B. M. Greenwood, and R. A. Adegbola. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: Randomised, double-blind, placebo-controlled trial. The Lancet 365(9465):1139-1146.

IOM (Institute of Medicine). 2008. Transcript of meeting one of the Committee on the Review of Priorities in the National Vaccine Plan. Washington, DC.

IOM Staff. 2008. IOM staff notes: Major themes from conversations with key individuals knowledgeable about the process of preparing the 1994 National Vaccine Plan. Washington, DC.

Iskander, J. 2007. Current CDC vaccine safety activities. Presentation at Vaccine Safety Evaluation: Post Marketing Surveillance Conference. Bethesda, MD.

Kaplan, R. S., and D. P. Norton. 1992. The balanced scorecard: Measures that drive performance. Harvard Business Review 70(1):71-79.

The Keystone Center. 2005. Citizen voices on pandemic flu choices: A report of the public engagement pilot project on pandemic influenza. (accessed June 3, 2008).

Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, N. Pierce, and the Vaccine Trialists Group. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine 349(14):1341-1348.

Lee, G. M., J. M. Santoli, and C. Hannan. 2007. Gaps in vaccine financing for underinsured children in the United States. Journal of the American Medical Association 298(6):638-643.

Milstien, J. B., M. Kaddar, and M. P. Kieny. 2006. The impact of globalization on vaccine development and availability. Health Affairs 25(4):1061-1069.

NIAID (National Institute of Allergy and Infectious Diseases). 1998. Task force on safer childhood vaccines: Final report and recommendations. Bethesda, MD: National Institues of Health.

NVAC (National Vaccine Advisory Committee). 2004. Public participation working group meeting on models for enhancing public involvement in vaccine decision-making meeting summary. (accessed May 22, 2008).

NVPO (National Vaccine Program Office). 1994. Disease prevention through vaccine development and immunization: The U.S. National Vaccine Plan—1994. Washington, DC: Department of Health and Human Services.

NVPO. 1997. NVPO Interagency group workshop agenda book. St. Michaels, MD: NVPO.

Orenstein, W. A. 2008. Draft priorities of the national vaccine plan. Presentation at Meeting One of the Committee on Review of Priorities in the National Vaccine Plan. Washington, DC.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement